经皮微波消融治疗Ⅰ期医学上无法手术的非小细胞肺癌：47例临床评估
Percutaneous microwave ablation of stage I medically inoperable non-small cell lung cancer: clinical evaluation of 47 cases.
作者信息
Yang Xia, Ye Xin, Zheng Aimin, Huang Guanghui, Ni Xiang, Wang Jiao, Han Xiaoying, Li Wenhong, Wei Zhigang
机构信息
Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.
出版信息
J Surg Oncol. 2014 Nov;110(6):758-63. doi: 10.1002/jso.23701. Epub 2014 Jun 25.
PURPOSE
To retrospectively evaluate safety and effectiveness of CT-guided percutaneous microwave ablation (MWA) in 47 patients with medically inoperable stage I peripheral non-small cell lung cancer (NSCLC).
METHODS
From February 2008 to October 2012, 47 patients with stage I medically inoperable NSCLC were treated in 47 MWA sessions. The clinical outcomes were evaluated. Complications after MWA were also summarized.
RESULTS
At a median follow-up period of 30 months, the median time to the first recurrence was 45.5 months. The local control rates at 1, 3, 5 years after MWA were 96%, 64%, and 48%, respectively. The median cancer-specific and median overall survivals were 47.4 and 33.8 months. The overall survival rates at 1, 2, 3, and 5 years after MWA were 89%, 63%, 43%, and 16%, respectively. Tumors ≤3.5 cm were associated with better survival than were tumors >3.5 cm. The complications after MWA included pneumothorax (63.8%), hemoptysis (31.9%), pleural effusion (34%), pulmonary infection (14.9%), and bronchopleural fistula (2.1%).
CONCLUSIONS
MWA is safe and effective for the treatment of medically inoperable stage I peripheral NSCLC.
目的
回顾性评估CT引导下经皮微波消融（MWA）治疗47例医学上无法手术的Ⅰ期周围型非小细胞肺癌（NSCLC）患者的安全性和有效性。
方法
2008年2月至2012年10月，47例医学上无法手术的Ⅰ期NSCLC患者接受了47次MWA治疗。评估临床结果。总结MWA后的并发症。
结果
中位随访期为30个月，首次复发的中位时间为45.5个月。MWA后1、3、5年的局部控制率分别为96%、64%和48%。癌症特异性中位生存期和总中位生存期分别为47.4个月和33.8个月。MWA后1、2、3和5年的总生存率分别为89%、63%、43%和16%。肿瘤≤3.5 cm的患者生存率优于肿瘤>3.5 cm的患者。MWA后的并发症包括气胸（63.8%）、咯血（31.9%）、胸腔积液（34%）、肺部感染（14.9%）和支气管胸膜瘘（2.1%）。
结论
MWA治疗医学上无法手术的Ⅰ期周围型NSCLC是安全有效的。
Zotero 插件